The US Food and Drug Administration (FDA) has accepted the filing of a new drug application (NDA) for Acer Therapeutics and Relief Therapeutics’ ACER-001 (sodium phenylbutyrate) to treat people with urea cycle disorders (UCDs).
AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m.
Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir).
UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China.
Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.
AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform.
Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine.
Canadian biotechnology firm AbCellera has signed a collaboration and licence agreement with Everest Medicines to advance new antibody therapies.
German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches.
Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.